Welcome to our dedicated page for Lifevantage SEC filings (Ticker: LFVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching for LifeVantage Corp’s latest consultant counts or product-line revenue without wading through dense text? Investors typically arrive here asking, “Where can I find LifeVantage’s quarterly earnings report 10-Q filing?” or “How do I track LifeVantage insider trading Form 4 transactions in real time?” This page bundles every SEC disclosure so you no longer jump between scattered EDGAR links.
Stock Titan’s AI reads each LifeVantage 8-K, 10-Q, and 10-K the moment it posts, then delivers plain-English summaries that flag shifts in independent-consultant enrollment, inventory risk and regulatory updates around nutrigenomic claims. Instead of skimming 200-plus pages, you’ll see the numbers that shape margins—net sales by product family, commission expense trends and emerging compliance issues—explained simply.
Use our quick-access tiles to drill into:
- Annual report 10-K simplified – pick out segment revenue, R&D on nutrigenomics and direct-sales compensation disclosures in minutes.
- Quarterly earnings report 10-Q – monitor consultant turnover, inventory levels and cash flow each quarter with AI-annotated highlights.
- Form 4 insider transactions – real-time alerts on LifeVantage executive stock moves so you can spot buying or selling trends fast.
- 8-K material events explained – leadership changes, product-safety notices or distributor policy updates distilled into key takeaways.
- Proxy statement executive compensation – understand how bonuses tie to enrolment growth and nutrigenomic product launches.
Whether you’re comparing quarters, dissecting compensation plans, or simply trying to “understand LifeVantage SEC documents with AI,” this hub keeps every filing current and comprehensible. Save hours, gain clarity, and turn regulatory disclosures into actionable insight.
Lifevantage Corp director Michael Beindorff reported gifting company stock to a family trust. On 11/25/2025, he transferred 7,819 shares of Lifevantage common stock in a transaction coded "G," which indicates a gift with a reported price of $0 per share.
After this transaction, he directly owned 27,570 shares and indirectly held 51,625 shares through the Michael A. Beindorff Trust, where he and his spouse are trustees. Additional indirect holdings include 126 shares held by his spouse as custodian for minor children and 5,500 shares held by his spouse.
LifeVantage Corporation disclosed that two senior executives plan to leave the company in December 2025. On December 3, 2025, Chief Marketing Officer Julie Boyster notified the company of her intention to resign from that role effective December 12, 2025 to pursue other business opportunities.
On the same date, Chief Information and Innovation Officer Todd Thompson informed LifeVantage that he intends to resign from his role effective December 24, 2025, also to pursue other business opportunities. These changes affect the leaders overseeing the company’s marketing and information/innovation functions.
LifeVantage Corp (LFVN)11/19/2025, a trust for which he and his spouse serve as trustees sold 12,607 shares of LifeVantage common stock at a weighted average price of $6.4198 per share, with individual trades executed between $6.39 and $6.48. After this transaction, he reported beneficial ownership of 43,806 shares held by the trust, 35,389 shares held directly, 126 shares held by his spouse as custodian for minor children, and 5,500 shares held by his spouse.
LifeVantage Corporation filed a Form S-8 to register securities for issuance under the LifeVantage Corporation 2017 Long‑Term Incentive Plan. The registration becomes effective upon filing in accordance with Rule 462(a).
The filing incorporates by reference the company’s most recent Form 10‑K, Form 10‑Q, and certain Form 8‑K reports. Exhibits include a legal opinion on the validity of the securities, auditor and counsel consents, and the plan document. The company states standard Delaware-law indemnification provisions for directors and officers and notes the SEC’s position that indemnification for Securities Act liabilities is unenforceable.
LifeVantage identifies itself as an accelerated filer and a smaller reporting company.
LifeVantage Corporation reported final results from its fiscal 2026 annual meeting held on November 6, 2025. Quorum was achieved with 9,571,454 shares (75.41%) represented out of 12,691,009 outstanding as of the record date.
All seven director nominees were elected. Stockholders approved, on an advisory basis, executive compensation with 7,420,820 votes for. They ratified Deloitte & Touche LLP as independent auditor with 9,539,267 votes for. An amendment to the 2017 Long‑Term Incentive Plan was approved with 5,382,441 votes for.
LifeVantage (LFVN) reported an insider equity grant. A director acquired 13,531 shares of common stock on 11/06/2025, reflected at $7.76 per share, which the filing notes equals the weighted average closing price over the ten trading days ending the day before the grant.
The grant will vest in a single installment on November 6, 2026, subject to the director’s continuous service. Following this grant, the director beneficially owns 23,999 shares, held directly.
LifeVantage (LFVN) reported a routine insider equity grant. Director Cynthia Latham acquired 13,531 shares of common stock on 11/06/2025 under the company’s outside director compensation program. The grant vests in a single installment on November 6, 2026, contingent on continuous service. The reported price of $7.76 reflects the weighted average closing price over the ten trading days preceding the grant date. Following this grant, her beneficial ownership stands at 64,879 shares, held directly.
Lifevantage (LFVN) reported a director equity grant. Director Raymond B. Greer acquired 13,531 shares of common stock on 11/06/2025 under the outside director compensation program at a price equal to the $7.76 weighted average closing price over the ten trading days ending the day before the grant.
The award will vest in a single installment on 11/06/2026, contingent on continued service. Following the grant, Greer beneficially owns 112,819 shares, held directly.
LifeVantage (LFVN) director Michael A. Beindorff reported insider activity on Form 4. On 11/06/2025, he received 13,531 shares under the outside director compensation program, scheduled to vest on November 6, 2026; the price shown is $7.76, equal to the weighted average closing price over the prior ten trading days. On 11/07/2025, he sold 1,000 shares at $7.33 (direct) and 35,000 shares at a weighted average $6.9215 (indirect via trust), with a portion sold to cover taxes from a restricted stock vesting. Following these transactions, holdings include 35,389 shares direct, 56,413 shares indirect via trust, 126 shares held by spouse as custodian for minor children, and 5,500 shares held by spouse.
LifeVantage (LFVN)13,531 shares of common stock under the company’s outside director compensation program. These shares will vest in a single installment on November 6, 2026.
The filing lists a price of $7.76, described as the weighted average closing price for the ten trading days ending the day before the grant date. Following the transaction, Judd beneficially owns 47,162 shares directly and 749,325 shares indirectly through Sudbury Capital Fund, LP.
FAQ
What is the current stock price of Lifevantage (LFVN)?
What is the market cap of Lifevantage (LFVN)?
